Chronic renal failure from lead: Myth or evidence-based fact

Kidney International

Volumn 79, Issue 3, 2011, Pages 272-279

  Evans, Marie ^a,b   Elinder, Carl Gustaf ^a,b  

^a KAROLINSKA INSTITUTE   (Sweden)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

chronic renal failure; clinical nephrology; epidemiology and outcomes; nephrotoxicity

Indexed keywords

5 AMINOLEVULINATE SYNTHASE; CHELATING AGENT; CREATININE; CYSTATIN C; EDETATE CALCIUM DISODIUM; LEAD; PROTOPORPHYRIN ZINC; SUCCIMER; UREA;

ACUTE KIDNEY FAILURE; BIOACCUMULATION; CHELATION THERAPY; CHRONIC KIDNEY DISEASE; CHRONIC KIDNEY FAILURE; CREATININE BLOOD LEVEL; CREATININE CLEARANCE; DISEASE ASSOCIATION; ENVIRONMENTAL EXPOSURE; ENZYME ACTIVATION; ENZYME ACTIVITY; GLOMERULUS FILTRATION RATE; HEME SYNTHESIS; HUMAN; HYPERTENSION; HYPERURICEMIA; INTERSTITIAL NEPHRITIS; KIDNEY PROXIMAL TUBULE; LEAD BLOOD LEVEL; LEAD POISONING; NONHUMAN; OCCUPATIONAL EXPOSURE; POPULATION EXPOSURE; PRIORITY JOURNAL; PROTEINURIA; REVIEW; TOXICITY TESTING; UREA BLOOD LEVEL; X RAY FLUORESCENCE;

EID: 78651389660     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1038/ki.2010.394     Document Type: Short Survey

References (84)

1. Nriagu JO. Saturnine gout among Roman aristocrats: did lead poisoning contribute to the fall of the Roman Empire? N Engl J Med 1983; 308: 660-663.
2. Wedeen R. Lead nephropathy. In: De Broe ME, Porter GA (eds). Clinical Nephrotoxins, 3rd edn. Springer Publishing Company, New York, 2008, pp 773-784.
3. WHO. Principles and Methods for the Assessment of Nephrotoxicity Associated with Exposure to Chemicals. World Health Organization (WHO): Geneva, 1991.
4. Brewster UC, Perazella MA. A review of chronic lead intoxication: an unrecognized cause of chronic kidney disease. Am J Med Sci 2004; 327: 341-347.
5. Staessen JA, Lauwerys RR, Buchet J-P et al. Impairment of renal function with increasing blood lead concentrations in the general population. N Engl J Med 1992; 327: 151-156.
6. Muntner P, He J, Vupputuri S et al. Blood lead and chronic kidney disease in the general United States population: results from III NHANES. Kidney Int 2003; 63: 1044-1050.
7. Menke A, Muntner P, Batuman V et al. Blood lead levels below 0.48 mmol/l (10 mg/dl) and mortality among US adults. Circulation 2006; 114: 1388-1394.
8. Schober SE, Mirel LB, Graubard BI et al. Blood lead levels and death from all causes, cardiovascular disease, and cancer: results from the III NHANES mortality study. Environ Health Perspect 2006; 114: 1538-1541.
9. Cheng Y, Schwartz J, Sparrow D et al. Bone lead and blood lead levels in relation to baseline blood pressure and the prospective development of hypertension the Normative Aging Study. Am J Epidemiol 2001; 153: 164-171. (Pubitemid 32060608)
10. Nawrot TS, Thjis L, Den Hond EM et al. An epidemiologic re-appraisal of the association between blood pressure and blood lead: a meta-analysis. J Hum Hypertens 2002; 16: 123-131.
11. Nawrot TS, Staessen JA. Low-level environmental exposure to lead unmasked as silent killer. Circulation 2006; 114: 1347-1349.
12. World Health Organization (WHO). Inorganic lead. In: Environmental Health Criteria 165 (Eds. International Program on Chemical Safety) World Health Organization, Geneva, 1995.
13. Ducroffre G. Lowering time trend of blood lead levels in Belgium since 1978. Environ Res 1990; 51: 25-34.
14. Muntner P, Menke A, DeSalvo KB et al. Continued decline in blood lead levels among adults in the United States. Arch Intern Med 2005; 165: 2155-2161.
15. Hu H, Milder FL, Burger DE. X-ray fluorescence measurements of lead burden in subjects with low-level community exposure. Arch Environ Health 1990; 45: 335-341.
16. Brangstrup Hansen JP, Døssing M, Paulev P-E. Chelatable lead body burden (by calcium-disodium EDTA) and blood lead concentration in man. J Occup Med 1981; 23: 39-43.
17. Tell I, Somervaille LJ, Nilsson U et al. Chelated lead and bone lead. Scand J Work Environ Health 1992; 18: 113-119.
18. Price J, Grudzinski AW, Craswell PW et al. Bone lead measurements in patients with chronic renal disease studied over time. Arch Environ Health 1992; 47: 330-335.
19. Rabinowitz M. Kinetic analysis of lead metabolism in healthy humans. J Clin Invest 1976; 58: 260-270.
20. Elinder C-G, Friberg L, Kjellstorm T, Nordberg G et al. (eds). Biological Monitoring of Metals: Chemical Safety Monographs: International Programme on Chemical Safety. World Health Organization: Geneva, Switzerland, 1994.
21. Leckie WJH, Tompsett SL. The diagnostic and therapeutic use of edathamil calcium disodium (EDTA, Versene) in excessive inorganic lead absorption. Q J Med 1958; 27: 65-81.
22. Emmerson BT. Chronic lead nephropathy: the diagnostic use of calcium EDTA and the association with gout. Australas Ann Med 1963; 12: 310-324.
23. Lin J-L, Yu C-C, Lin-Tan D-T et al. Lead chelation therapy and urate excretion in patients with chronic renal diseases and gout. Kidney Int 2001; 60: 266-271.
24. Hu H, Rabinowitz M, Smith D. Bone lead as a biological marker in epidemiologic studies of chronic toxicity: conceptual paradigms. Environ Health Perspect 1998; 106: 1-8.
25. Craswell PW, Price J, Boyle PD et al. Chronic renal failure with gout: a marker of chronic lead poisoning. Kidney Int 1984; 26: 319-323.
26. World Health Organization. Lead, Chapter 6.7. In: Air Quality Guidelines (Eds. WHO Regional Office for Europe) WHO Regional Publications, European Series, No 91: Copenhagen, Denmark, 2000.
27. Fontanellas A, Navarro S, Moran-Jimenez M-J et al. Erythrocyte aminolevulinate dehydratase activity as a lead marker in patients with chronic renal failure. Am J Kidney Dis 2002; 40: 43-50.
28. Goyer R. Mechanisms of cadmium and lead nephropathy. Toxicol Let 1989; 46: 153-162.
29. Moore J, Goyer R. Lead-induced inclusion bodies: composition and probable role in lead metabolism. Environ Health Perspect 1974; 7: 121-127.
30. Moore J, Goyer R, Wilson M. Lead induced inclusion bodies. Solubility, amino acid content, and relationship to residual acidic nuclear proteins. Lab Invest 1973; 29: 488-494.
31. Wedeen R, Malik D, Batuman V. Detection and treatment of occupational lead exposure. Arch Intern Med 1979; 139: 52-57.
32. Cardenas A, Roels H, Bernard AM et al. Markers of early renal changes induced by industrial pollutants. II. Application to workers exposed to lead. Br J Ind Med 1993; 50: 28-36. (Pubitemid 23030201)
33. Fels LM, Herbort C, Pergande M et al. Nephron target sites in chronic exposure to lead. Nephrol Dial Transplant 1994; 9: 1740-1746.
34. Khalil-Manesh F, Gonick HC, Cohen A. Experimental model of lead nephropathy. III. Continuous low-level lead administration. Arch Environ Health 1993; 48: 271-278.
35. Khalil-Manesh F, Gonick HC, Cohen A et al. Experimental model of lead nephropathy. I. Continuous high-dose lead administration. Kidney Int 1992; 41: 1192-1203.
36. Khalil-Manesh F, Gonick HC, Cohen A et al. Experimental model of lead nephropathy II. Effect of removal from lead exposure and chelation treatment with dimercaptosuccinic acid (DMSA). Environ Res 1992; 58: 35-54.
37. Sanchez-Fructuoso AI, Blanco J, Cano M et al. Experimental lead nephropathy: treatment with calcium disodium ehylenediaminetetraacetate. Am J Kidney Dis 2002; 40: 59-67.
38. Nye L. An investigation of the extraordinary incidence of chronic nephritis in young people in Queensland. Med J Aust 1929; 2: 145-159.
39. Henderson D. A follow-up of cases with plumbism in children. Aust Ann Med 1954; 3: 219-224.
40. Moel DI, Sachs HK. Renal function 17 to 23 years after chelation therapy for childhood plumbism. Kidney Int 1992; 42: 1226-1231.
41. Hu H. A 50-year follow-up of childhood plumbism: hypertension, renal function, and hemoglobin levels among survivors. AJDC 1991; 145: 681-687.
42. Staessen JA, Nawrot TS, Den Hond EM et al. Renal function, cytogenetic measures, and sexual development in adolencents in relation to environmental pollutants: a feasibility study of biomarkers. Lancet 2001; 357: 1660-1669.
43. Fadrowski JJ, Navas-Acien A, Tellez-Plaza M et al. Blood lead level and kidney function in US adolescents. Arch Intern Med 2010; 170: 75-82.
44. Hsiao C-Y, Wu H-DI, Lai J-S et al. A longitudinal study of the effects of long-term exposure to lead among lead battery factory workers in Taiwan (1989-1999). Sci Total Environ 2001; 279: 151-158.
45. Weaver VM, Griswold M, Todd AC et al. Longitudinal associations between lead dose and renal function in lead workers. Environ Res 2009; 109: 101-107.
46. Pinto de Almeida AR, Carvalho FM, Spinola AG et al. Renal dysfunction in Brazilian lead workers. Am J Nephrol 1987; 7: 455-458.
47. Ehrlich R, Robins T, Jordaan E et al. Lead absorption and renal dysfunction in a South African Battery factory. Occup Environ Med 1998; 55: 453-460.
48. Hallan SI, Coresh J, Astor BC et al. International comparison of the relationship of chronic kidney disease prevalence and ESRD risk. J Am Soc Nephrol 2006; 17: 2275-2284.
49. Evans M, Fored CM, Nise G et al. Occupational lead exposure and severe CKD: a population-based case-control and prospective observational cohort study in Sweden. Am J Kidney Dis 2010; 55: 497-506.
50. Staessen JA, Yeoman WB, Fletcher AE et al. Blood lead concentration, renal function, and blood pressure in London civil servants. Br J Ind Med 1990; 47: 442-447.
51. Payton M, Hu H, Sparrow D et al. Low-level exposure and renal function in the normative aging study. Am J Epidemiol 1994; 140: 821-829.
52. Hernández-Serrato MI, Fortoul TI, Rojas-Martínez R et al. Lead blood concentrations and renal function evaluation: study in an exposed Mexican population. Environ Res 2006; 100: 227-231.
53. Akesson A, Lundh T, Vahter M et al. Tubular and glomerular kidney effects in Swedish women with low environmental cadmium exposure. Environ Health Perspect 2005; 113: 1627-1631.
54. De Burbure C, Buchet J-P, Leroyer A et al. Renal and neurologic effects of cadmium, lead, mercury, and arsenic in children: evidence of early effects and multiple interactions at environmental exposure levels. Environ Health Perspect 2006; 114: 584-590.
55. Pocock SJ, Shaper AG, Ashby D et al. Blood lead concentration, blood pressure and renal function. BMJ 1984; 289: 872-874.
56. Kim R, Rotnitzky A, Sparrow D et al. A longitudinal study of low-level lead exposure and impairment of renal function. JAMA 1996; 275: 1177-1181.
57. Tsaih S-W, Korrick S, Schwartz J et al. Lead, diabetes, hypertension, and renal function: the normative aging study. Environ Health Perspect 2004; 112: 1178-1182.
58. Siemiatycki J, Fritschi L, Nadon L et al. Reliability of an expert rating procedure for retrospective assessment of occupational exposures in community-based case-control studies. Am J Ind Med 1997; 31: 280-286.
59. Nuyts GD, Van Vlem E, Thys J et al. New occupational risk factors for chronic renal failure. Lancet 1995; 346: 7-11.
60. Steenland NK, Thun MJ, Ferguson CW et al. Occupational and other exposures associated with male end-stage renal disease: a case/control study. Am J Public Health 1990; 80: 153-157.
61. Muntner P, Menke A, Batuman V et al. Association of tibia lead and blood lead with end-stage renal disease: a pilot study of African Americans. Environ Res 2007; 104: 396-401.
62. Lin J-L, Tan D-T, Hsu K-H et al. Environmental lead exposure and progressive renal insufficiency. Arch Intern Med 2001; 161: 264-271.
63. Yu C-C, Lin J-L, Lin-Tan D-T. Environmental exposure to lead and progression to chronic renal disease: a four year prospective longitudinal study. J Am Soc Nephrol 2004; 15: 1016-1022.
64. Lin J-L, Lin-Tan D-T, Hsu K-H et al. Environmental lead exposure and progression of chronic renal diseases in patients without diabetes. N Engl J Med 2003; 348: 277-286.
65. Lin J-L, Lin-Tan D-T, Li Y-J et al. Low-level environmental exposure to lead and progressive chronic kidney diseases. Am J Med 2006; 119: 707.e701-e707.e709.
66. Friberg L, Vahter M. Assessment of exposure to lead and cadmium through biological monitoring: results of a UNEP/WHO global study. Environ Res 1983; 30: 95-128.
67. Roels H, Lauwerys RR, Konings J et al. Renal function and hyperfiltration capacity in lead smelter workers with high bone lead. Occup Environ Med 1994; 51: 505-512.
68. Elinder CG, Edling C, Lindberg E et al. Assessment of renal function in workers previously exposed to cadmium. Br J Ind Med 1985; 42: 754-760.
69. Van de Vyver FL, D'Haese PC, Visier WJ et al. Bone lead in dialysis patients. Kidney Int 1988; 33: 601-607.
70. Bennett WM. Lead nephropathy. Kidney Int 1985; 28: 212-220.
71. Greenberg A, Parkinson DK, Fetterolf DE et al. Effects of elevated lead and cadmium burdens on renal function and calcium metabolism. Arch Environ Health 1986; 41: 69-76.
72. Pollock CA, Ibels LS. Lead intoxication in paint removal workers on the Sydney Harbor Bridge. Med J Aust 1986; 145: 635-639.
73. Verschoor M, Wibowo A, Herber R et al. Influence of occupational low-level lead exposure on renal parameters. Am J Ind Med 1987; 12: 341-351.
74. De Kort W, Verschoor M, Wibowo A et al. Occupational exposure to lead and blood pressure: a study in 105 workers. Am J Ind Med 1987; 11: 145-156.
75. Ong C, Endo G, Chia K. Evaluation of renal function in workers with low blood lead levels. In: FOA V (ed). Occupational and Environmental Chemical Hazards. Ellis Horwood Ltd: Chichester, 1987, pp 327-333.
76. Maranelli G, Apostoli P. Assessment of renal function in lead poisoned workers. In: FOA V (ed). Occupational and Environmental Chemical Hazards. Ellis Horwood Ltd: Chichester, 1987, pp 344-348.
77. Omae K, Sakurai H, Higashi T et al. No adverse effects of lead on renal function in lead exposed workers. Industrial health 1990; 28: 77-83.
78. Gennart J, Bernard A, Lauwerys R. Assessment of thyroid, testes, kidney and autonomic nervous system function in lead-exposed workers. Int Arch Occup Environ Health 1992; 64: 49-57.
79. Gerhardsson L, Chettle DR, Englyst V et al. Kidney effects in long term exposed lead smelter workers. Br J Ind Med 1992; 49: 186-192.
80. Kumar BD, Krishnaswamy K. Detection of occupational lead nephropathy using early renal markers. Clin Toxicol 1995; 33: 331-335.
81. Lim YC, Chia KS, Ong HY et al. Renal dysfunction in workers exposed to inorganic lead. Ann Acad Med 2001; 30: 112-117.
82. Wang V-S, Lee M-T, Chiou J-Y et al. Relationship between blood lead levels and renal function in lead battery workers. Int Arch Occup Environ Health 2002; 75: 569-575.
83. Weaver VM, Jaar BG, Schwartz BS et al. Associations among lead dose biomarkers, uric acid, and renal function in Korean lead workers. Environ Health Perspect 2005; 113: 36-42.
84. Orisakwe O, Nwachukwu E, Osadolor H et al. Liver and kidney function tests amongst paint factory workers in Nkpor, Nigeria. Toxicol Ind Health 2007; 23: 161-165.